Italia markets closed

Arrowhead Pharmaceuticals, Inc. (0HI3.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
32,79+0,64 (+1,98%)
Alla chiusura: 03:33PM GMT

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400
https://arrowheadpharma.com

Settore/i
Settore
Impiegati a tempo pieno397

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Christopher R. Anzalone Ph.D.CEO, Pres & Director1,68M6,71M1969
Mr. Kenneth A. MyszkowskiChief Financial Officer729,77k3,78M1966
Mr. Patrick O'Brien J.D., PharmDCOO & Gen. Counsel733,13k7,49M1964
Dr. James C. Hamilton M.D., MBAChief of Discovery & Translational Medicine673,45kN/D1978
Dr. Javier San Martin M.D.Chief Medical Officer658,48kN/D1965
Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoN/DN/DN/D
Dr. Vincent Anzalone CFAHead of Investor Relations & VPN/DN/DN/D
Mr. Howard LovyDirector of CommunicationsN/DN/DN/D
Dr. Mark SeefeldHead of Toxicology & VPN/DN/D1954
Ms. Tracie OliverChief Commercial OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Governance aziendale

L'ISS Governance QualityScore di Arrowhead Pharmaceuticals, Inc. al 1 gennaio 2023 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.